Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I clinical trial of dextromethorphan in intractable partial epilepsy.

Methods and findings in experimental and clinical pharmacology - 1 Dec 1999

Kimiskidis V K, Mirtsou-Fidani V, Papaioannidou P G, Niopas I, Georgiadis G, Constadinidis T C, Kazis A D

Abstract excerpt

We conducted an open-label pilot study of dextromethorphan (DM) in intractable partial epilepsy with the following objectives: a preliminary evaluation of the drug's safety and efficacy in the epileptic patient and a definition of a concentration range which can be safely achieved in future studies. Sixteen patients with drug-resistant, localization-related epilepsies entered the trial. After an 8-week baseline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epilepsies, Partial
Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dextromethorphan

Share to Drug Resistance

Share to Phenotype

Share to Pilot Projects

Source

Identifiers

PMID: 10702964
DOI: 10.1358/mf.1999.21.10.795765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I clinical trial of dextromethorphan in intractable partial epilepsy.PMID 10702964Read ↗

Fluoroalkylation of Dextromethorphan Improves CNS Exposure and Metabolic StabilitySemantic proximity Read ↗

Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.Semantic proximity Read ↗

A rapid thin layer chromatographic procedure to identify poor and extensive oxidative drug metabolizers in man using dextromethorphan.Semantic proximity Read ↗

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Semantic proximity Read ↗

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.Semantic proximity Read ↗

Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan.Semantic proximity Read ↗

Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects.Semantic proximity Read ↗

Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.Semantic proximity Read ↗

[Genetic and environmental effects on neuromodulation and the antinociceptive effect of dextromethorphan].Semantic proximity Read ↗

Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.Semantic proximity Read ↗

Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.Semantic proximity Read ↗

Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.